Lava Therapeutics Nv's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Lava Therapeutics Nv (LVTX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Lava Therapeutics Nv's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Lava Therapeutics Nv | - | - | - | Yes |
| High-Confidence Competitors (7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
LVTX Stock Performance relative to its Competitors
LVTX Stock Performance relative to High-Confidence Competitors
Lava Therapeutics Nv's Comment on Competition and Industry Peers
Lava Therapeutics Nv's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Immatics Biotechnologies GmbH | Named by the company | 85% |
| Sandhill Therapeutics, Inc | Named by the company | 85% |
| Biosion USA Inc. | Named by the company | 85% |
| Gadeta BV | Named by the company | 85% |
| Leucid Bio Ltd | Named by the company | 85% |
| TC BioPharm Limited | Named by the company | 85% |
| Acepodia Inc. | Named by the company | 85% |
| Editas Medicine, Inc. | Named by the company | 85% |
| Immatics N.V. | Named by the company | 85% |
| Shattuck Labs Inc. | Named by the company | 85% |
| Clade Therapeutics | Named by the company | 85% |
| ImCheck Therapeutics SAS | Named by the company | 85% |
| PhosphoGam Inc. | Named by the company | 85% |
| Adicet Bio, Inc. | Named by the company | 85% |
| Eureka Therapeutics, Inc. | Named by the company | 85% |
| IN8bio, Inc. | Named by the company | 85% |
| Takeda Pharmaceutical Company Ltd | Named by the company | 85% |
| Aptevo Therapeutics Inc | Named by the company | 85% |
| Cytomed Therapeutics, Ltd. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Lava Therapeutics Nv's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.